BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 24.66 USD -0.52% Market Closed
Market Cap: 4.6B USD
Have any thoughts about
BridgeBio Pharma Inc?
Write Note

BridgeBio Pharma Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BridgeBio Pharma Inc
Cost of Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
BridgeBio Pharma Inc
NASDAQ:BBIO
Cost of Revenue
-$2.4m
CAGR 3-Years
-15%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.2B
CAGR 3-Years
-1%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-5%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$12.9B
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.5B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
0%
CAGR 5-Years
-22%
CAGR 10-Years
-25%

See Also

What is BridgeBio Pharma Inc's Cost of Revenue?
Cost of Revenue
-2.4m USD

Based on the financial report for Sep 30, 2024, BridgeBio Pharma Inc's Cost of Revenue amounts to -2.4m USD.

What is BridgeBio Pharma Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
1%

Over the last year, the Cost of Revenue growth was 4%. The average annual Cost of Revenue growth rates for BridgeBio Pharma Inc have been -15% over the past three years , 1% over the past five years .

Back to Top